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1 |  INTRODUCTION
Combined malonic and methylmalonic aciduria, or 
CMAMMA, is a rare disease for which the ACSF3 gene 
(OMIM #614265) was recently identified by exome sequenc-
ing as the most common underlying genetic cause (Alfares 
et al., 2011; Sloan et al., 2011). The ACSF3 gene encodes a 
mitochondrial malonyl- and methylmalonyl- CoA synthetase, 
which acylates malonic and methylmalonic acid to their 
CoA derivatives for further use in mitochondrial metabolism 
(Bowman & Wolfgang, 2019). The clinical phenotype of 
this recently described condition is variable, and the natural 
history remains to be fully defined. Although some reports 
describe severe symptoms and signs, including metabolic ac-
idosis, developmental delay, gastrointestinal disease, failure 
to thrive, seizures, cardiomyopathy, and dysmorphic facial 
Received: 1 December 2020 | Revised: 25 January 2021 | Accepted: 29 January 2021
DOI: 10.1002/mgg3.1621  
O R I G I N A L  A R T I C L E
Considerations of expanded carrier screening: Lessons learned 
from combined malonic and methylmalonic aciduria
Marie Cosette Gabriel1  |   Stephanie M. Rice2 |   Jennifer L. Sloan3 |    
Matthew H. Mossayebi2  |   Charles P. Venditti3 |   Huda B. Al- Kouatly2
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial- NoDerivs License, which permits use and distribution in any medium, 
provided the original work is properly cited, the use is non- commercial and no modifications or adaptations are made.
© 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
1Department of Obstetrics and 
Gynecology, Cooper University Hospital, 
Camden, NJ, USA
2Division of Maternal- Fetal Medicine, 
Department of Obstetrics and 
Gynecology, Sidney Kimmel Medical 
College of Thomas Jefferson University, 
Philadelphia, PA, USA
3National Human Genome Research 
Institute, National Institutes of Health, 
Bethesda, MD, USA
Correspondence
Huda B. Al- Kouatly, Division of 
Maternal- Fetal Medicine, Department 
of Obstetrics and Gynecology, Thomas 
Jefferson University, 833 Chestnut Street, 
Floor 1, Philadelphia, PA 19107, USA.
Email: Huda.Al-Kouatly@jefferson.edu
Abstract
Background: Expanded carrier screening (ECS) utilizes high- throughput next- 
generation sequencing to evaluate an individual's carrier status for multiple condi-
tions. Combined malonic and methylmalonic aciduria (CMAMMA) due to ACSF3 
deficiency is a rare inherited disease included in such screening panels. Some cases 
have been reported with metabolic symptoms in childhood yet other cases describe a 
benign clinical course, suggesting the clinical phenotype is not well defined.
Methods/Case Report: Clinical and laboratory findings during the prenatal period 
were obtained retrospectively from medical records.
Results: A 37- year- old nulliparous woman and her partner were each identified as 
carriers of ACSF3 variants and presented at 9 weeks gestation for prenatal genetic 
consultation. The couple received extensive genetic counseling and proceeded with 
chorionic villus sampling at 11 weeks gestation. Subsequent analysis confirmed that 
the fetus inherited both parental ACSF variants. The couple was devastated by the 
results and after reviewing options of pregnancy continuation and termination, they 
decided to terminate the pregnancy. Following this decision, the patient was diag-
nosed with acute stress disorder.
Conclusion: This case highlights how expanded carrier screening adds complexity to 
reproductive decision- making. Stronger guidelines and additional research are needed 
to direct and evaluate the timing, composition, and implementation of ECS panels.
K E Y W O R D S
ACSF, CMAMMA, expanded carrier screening, genetic counseling
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features, others document a benign clinical course in affected 
adults and children (Alfares et al., 2011; Sloan et al., 2011). 
In this report, we describe a couple referred for reproductive 
genetic counseling, each identified as carriers of ACSF3 vari-
ants through expanded carrier screening, and discuss how the 
genetic results affected their reproductive decision- making.
2 |  CASE
A 37- year- old G2P0010 woman and her partner presented 
for reproductive genetic counseling at 9w2d gestation. Prior 
to the visit, the patient and her partner had pursued fertil-
ity treatment and had undergone expanded genetic carrier 
screening as part of their preconception evaluation, where 
they were identified as carriers of ACSF3. The patient was 
heterozygous for the pathogenic c.1672C>T (p.R558W) 
variant, while her partner was found to carry the likely path-
ogenic variant c.1608G>A (p.W536X). They were in the 
process of seeking preimplantation genetic testing for this 
condition when they spontaneously conceived the current 
pregnancy. They subsequently presented to reproductive ge-
netic counseling to discuss options for prenatal genetic diag-
nosis. The couple was counseled on the broad spectrum of 
the phenotype and the possibility of the fetus being clinically 
unaffected despite inheriting both parental variants. The cou-
ple proceeded with chorionic villus sampling (CVS) that was 
performed at 11w5d gestation. Direct- targeted analysis of 
the parental variants confirmed that the fetus inherited both 
parental ACSF3 variants. The couple was devastated by the 
results and after reviewing options of pregnancy continuation 
and termination, they decided to terminate the pregnancy. 
Following this decision, the patient was diagnosed with acute 
stress disorder.
3 |  METHODS
3.1 | Ethical compliance
IRB approval from Thomas Jefferson University is not re-
quired for case report publications. Consent has been ob-
tained from the patient.
3.2 | Genetic information
The GenBank version number for ACSF3  has the NCBI 
Reference Sequence: NG_031961.1. The c.1672C>T 
(p.R558W) variant discussed in this case has been reported 
in the Ensembl database as a mutation in exon 11 of the gene, 
transcript: ENST00000317447. The c.1608G>A (p.W536X) 
variant discussed in this case has been reported in the 
Ensembl database as a mutation in exon 10 of the gene, tran-
script: ENST00000317447.
4 |  DISCUSSION
Reproductive carrier screening is an important component of 
preconception and prenatal care, and seeks to identify couples 
at risk for conceiving a child with a particular genetic condi-
tion. Carrier screening began in the 1970s with the discovery 
of the biochemical cause of Tay- Sachs disease (Wapner & 
Biggio, 2019). Programs aimed at identifying carriers of this 
disease in the Jewish community helped to significantly de-
crease the incidence of this severe and devastating disorder, 
and in turn, became the model for community and ethnic- 
based screening programs. Expanded carrier screening 
(ECS) utilizes high- throughput next- generation sequencing 
to evaluate an individual's carrier status for multiple condi-
tions. ACOG Committee Opinion #690 states that “expanded 
carrier screening is an acceptable screening strategy for pre-
conception and prenatal carrier screening that must be tied to 
appropriate counseling in a shared decision- making process 
between physician and patient (ACOG, 2017).” Additional 
considerations for carrier screening include prevalence of the 
condition, carrier frequency of mutant alleles, detection rates, 
age of onset, condition severity and residual risk (Edwards 
et al., 2015). In 2009, the advent of next- generation sequenc-
ing enabled the identification of multiple disorders without 
regard for the considerations delineated in current screening 
guidelines, and has resulted in expanded carrier screening 
(Haque et al., 2016).
Although the goal of ECS is to inform reproductive 
decision- making, the rapid expansion of commercial labo-
ratory genetic testing, fueled by corporate competition, has 
extended the scope of the panel to include disorders beyond 
those specified in recommended screening guidelines. At 
this time, there are currently no specific guidelines regard-
ing which disorders should be included on ECS panels. Per 
the American College of Obstetricians and Gynecologists 
(ACOG), ECS should meet several of the following crite-
ria: (a) a carrier frequency of 1 in 100 or greater; (b) a well- 
defined phenotype; (c) a detrimental effect on quality of life; 
(d) causes cognitive or physical impairment; (e) requires sur-
gical or medical intervention; or (f) has onset early in life. 
The American College of Genetics and Genomics (ACMG) 
adopts a similar stance; however, ACMG’s criteria provide 
more structured guidance. For example, ACMG agrees that a 
condition should have a well- defined phenotype. ACMG also 
asserts that in cases of variable expressivity, incomplete pen-
etrance, and for disorders associated with a mild phenotype, 
inclusion of such disorders on screening panels should be 
optional and transparent to facilitate reproductive decision- 
making (Grody et al., 2013). The aforementioned criteria 
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from these two well- established professional organizations 
serve practitioners with guidelines to determine which con-
ditions should be included on ECS; however, neither set of 
guidelines recommends specific disorders to be tested. The 
criteria are vague and leave room for interpretation, espe-
cially those set forth by ACOG. At this time, the content of 
ECS panels has been dictated by commercial laboratories, 
and there is significant variation in gene/disease content be-
tween panels. In a study comparing 16 ECS providers, the 
range of recessive disorders screened for was found to be 41 – 
1792 and the number of genes ranged from 40 to 1556. More 
striking, is that of the genes screened for by these panels 
only three genes were screened by all 16 panels (Chokoshvili 
et al., 2018). Due to ambiguity in the guidelines set forth by 
ACOG and ACMG, commercial laboratories are able to offer 
larger multi- gene panels, often at the same price as a smaller 
panel of genes. Although patients may instinctively be drawn 
to larger expanded carrier screening panels, they are often 
unaware of the implications of positive results, and thus 
unable to contextualize the importance of genetic testing. 
Although ACOG and ACMG provide criteria that should be 
met for inclusion on an expanded carrier screening panel, we 
suggest forming a task force to create a list of recommended 
genes for an expanded carrier screening panel based on these 
criteria. A similar list was developed by ACMG for genes 
associated with adult- onset medically actionable conditions. 
This list of 59 genes provides guidance for reporting the 
appropriate secondary findings on whole genome or whole 
exome sequencing.
The couple we present faced a 25% risk of having a fetus 
with CMAMMA and utilized diagnostic testing to confirm 
the fetus inherited both pathogenic variants. Neither the par-
ents nor their healthcare advocates were able to qualify how 
CMAMMA would manifest, given the variability in clinical 
phenotype. Thus, even though ECS informed this couple's 
reproductive decision- making, it led them to more questions 
and uncertainty. As a result, practitioners and patients are left 
to determine whether “bigger” is actually “better” when de-
ciding which panel to select, especially since cost tends not to 
vary much with the size of the panel.
CMAMMA due to ACSF3 deficiency is a condition that, 
despite having specific biochemical manifestations, lacks a 
well- defined clinical phenotype. In some reported cases of 
CMAMMA, the disease has a detrimental effect on the qual-
ity of life; however, in others, the disease presents with a clin-
ically benign course. It may or may not cause cognitive or 
physical impairment, and it may or may not require medical 
intervention. Finally, the disease may present in children or 
adults. Thus, in some cases of CMAMMA, the disease meets 
the ACOG criteria for inclusion on an ECS panel and in other 
cases, it meets none (Sloane et al., 2011).
Approximately 4 hours over the course of three different 
Maternal- Fetal Medicine Genetics appointments were spent 
counseling this couple. Although the couple understood that 
the fetus could be clinically asymptomatic despite inheriting 
two pathogenic variants, they ultimately decided to terminate 
the pregnancy. This decision later had a significant influence 
on the patient's emotional and psychological state, to the point 
where she was diagnosed with acute stress disorder. This 
case demonstrates the need to evaluate the impact of ECS on 
patients and healthcare organizations, while paying special 
attention to the components of carrier screening panels, the 
extra demands on genetic and reproductive counseling, the 
burden of cost, and the patient's emotional and psychological 
well- being (Wapner & Biggio, 2019).
Beyond consideration of how to implement the suggested 
criteria for inclusion of disorders on ECS panels and the 
counseling required by use of such panels, it is important 
to consider the impact of the information attained by ECS 
panels. Guo and Gregg (2019) used population data to esti-
mate gene carrier rates of pathogenic and likely pathogenic 
variants associated with a severe recessive condition. They 
then simulated hypothetical ECS panels and discovered that 
although gene carrier rates are high for any panel of genes, 
the proportion of at- risk couples is comparatively much 
lower. They posit that when considering what to include on 
a screening panel, three main costs should be considered: 
(a) technical cost; (b) cost of interpretation and counseling; 
(c) and cost of anxiety to the patient. In a joint statement of 
the American College of Medical Genetics and Genomics, 
American College of Obstetricians and Gynecologists, 
National Society of Genetic Counselors, Perinatal Quality 
Foundation, and Society for Maternal- Fetal Medicine, fur-
ther research on the following areas is suggested for optimal 
implementation of expanded carrier screening: curated data 
repository of variants and phenotypes, education of health-
care providers and patients, educational resources for provid-
ers and patients, evaluation of patient and provider attitudes 
toward ECS, and cost of ECS (Grody et al., 2013). While the 
discussion regarding recommendations and considerations 
for ECS continues, more specific guidance on what to include 
on these panels is needed. The ambiguity allows companies 
offering ECS to disregard this discussion and compete in the 
marketplace using the number of genes on their panels as a 
selling point (Edwards et al., 2015). Clinicians lack the ap-
propriate resources to counsel patients on the wide variety of 
disorders included in ECS and are often attempting to coun-
sel patients after the results become available. Caution must 
be exercised as ECS continues to participate in preconception 
and prenatal decision- making, and more specific guidance is 
needed to evaluate the timing, composition, and implementa-
tion of ECS panels. Thorough pre- test counseling is strongly 
recommended prior to ordering expanded carrier screening 
for a patient. Patients should be informed that the clinical 
spectrum of some disorders on the test's panel is poorly un-
derstood; however, our knowledge of these conditions will 
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likely improve over time as expanded carrier screening be-
comes more commonplace and more data become available. 
In particular disorders where the phenotype is variable as in 
CMAMMA, we suggest natural history studies be performed 
to guide inclusion or exclusion on ECS. Expanded carrier 
screening empowers patients with knowledge of their carrier 
status; yet, it can also leave patients and healthcare providers 
struggling to apply and understand this knowledge and how it 
pertains to pregnancy.
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